-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Alnylam Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2010 to 2023.
- Alnylam Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$31.8M, a 49.7% increase year-over-year.
- Alnylam Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was -$133M, a 10.4% increase year-over-year.
- Alnylam Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was -$151M, a 55.7% increase from 2022.
- Alnylam Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was -$342M, a 138% decline from 2021.
- Alnylam Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$143M, a 428% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)